Fairs fair guys.
Olef has a valid point.
The company at least partly blamed the failed trial on the strong efficacy of standard care, potentially obfuscating what ever VF001 was (or was not doing).
Why then, would you abandon trails in other indications where SC is severely lacking (e.g. the ocular program).
You’d only abandon all trials if you thought the drug lacked clinical activity.
Fairs fair guys. Olef has a valid point. The company at least...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DLM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| DLM (ASX) Chart |
Day chart unavailable